Vera Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
VERA Nasdaq 8731 https://veratx.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Vera Therapeutics Inc

Health Care Roundup: Market Talk - Apr 23rd, 2024 9:09 pm
Could This Stock Be the Next Biotech Buyout? - Apr 13th, 2024 9:29 am
Insider Sells at Vera Therapeutics Inc: SVP, Finance, Chief Accounting Officer Joseph Young ... - Apr 12th, 2024 11:01 pm
Vertex Pharmaceuticals to buy Alpine Immune Sciences in $4.9B deal - Apr 11th, 2024 8:29 pm
ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors - Apr 5th, 2024 10:30 pm
Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress - Apr 2nd, 2024 12:00 pm
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results - Mar 20th, 2024 11:30 am
Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference - Feb 28th, 2024 9:20 pm
Estimating The Fair Value Of Vera Therapeutics, Inc. (NASDAQ:VERA) - Feb 11th, 2024 1:23 pm
Vera Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference - Feb 2nd, 2024 1:00 pm
Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Class A Common Stock - Feb 1st, 2024 9:05 pm
Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock - Jan 30th, 2024 4:50 am
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock - Jan 29th, 2024 11:15 am
Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy - Jan 25th, 2024 11:30 am
Why Vera Therapeutics Stock Soared by 22% This Week - Jan 12th, 2024 11:44 pm
Vera Therapeutics Announces Appointment of Industry Veterans Robert Brenner, M.D. as Chief Medical Officer and William D. Turner as Chief Development Officer - Jan 8th, 2024 1:01 pm
Vera Therapeutics to Host In-Person R&D Day in New York to Present Week 72 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN on January 25, 2024 - Jan 8th, 2024 1:00 pm
Pleasing Signs As A Number Of Insiders Buy Vera Therapeutics Stock - Jan 1st, 2024 11:06 am
Vera Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference - Dec 27th, 2023 1:00 pm
This Promising Small-Cap Biotech Stock Could Rise 70%, According to Wall Street - Dec 15th, 2023 3:15 pm